Zentalis Pharmaceuticals Rated by Brokers, Director Ups Stock

Summary

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) received a consensus rating of ‘Hold’ from nine brokerage firms, with five analysts recommending to hold and four recommending to buy. The 12-month average target price is $8.24. The stock opened at $1.51, with a 12-month low of $1.01 and a high of $8.87. Recently, Director Scott Dunseth Myers purchased 21,000 shares at $1.40 each. Institutional investors have also been active, acquiring new shares in the company.Market Beat

Impact Analysis

This event is at the company level, as it specifically pertains to Zentalis Pharmaceuticals. The consensus rating of ‘Hold’ indicates a neutral stance from analysts, suggesting that the current stock price may be fairly valued. The purchase of shares by Director Scott Dunseth Myers, along with increased institutional ownership, could signal confidence in the company’s future prospects, possibly influencing investor perception positively and leading to increased investor interest. However, the stock’s past volatility, with a wide 12-month price range, indicates potential risks. Investors might consider evaluating Zentalis based on upcoming drug developments, market strategy, and financial health to determine buy or hold strategies.Market Beat